Harmony Outcomes — albiglutide
The cardiovascular outcome trial for albiglutide, a compound subsequently withdrawn from the market for commercial reasons rather than for safety. No albiglutide monograph is held; the programme is recorded against the dulaglutide monograph, which covers the albumin- and Fc-fused long-acting class.
The cardiovascular outcome trial for albiglutide, a compound subsequently withdrawn from the market for commercial reasons rather than for safety. No albiglutide monograph is held; the programme is recorded against the dulaglutide monograph, which covers the albumin- and Fc-fused long-acting class.
Sponsor class: Manufacturer-sponsored. First record: 2015.
Records in this programme
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| HARMONY-OUTCOMES | Dulaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,463 | 2018 | Moderate |
| HARMONY-OUTCOMES-ADHERENCEprogramme record | Dulaglutide | Phase 3 | Reported | Observational | — | 2018 | Very low |
| HARMONY-OUTCOMES-BODY-COMPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |